Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    "methodist hospital" | Open Studies | "Carcinoma, Non-Small-Cell Lung" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: anti-B7H1 monoclonal antibody MEDI4736;   Drug: PI3 kinase inhibitor GDC-0032;   Drug: palbociclib isethionate;   Drug: FGFR inhibitor AZD4547;   Biological: rilotumumab;   Drug: docetaxel;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
2 Recruiting Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Conditions: Bronchioloalveolar Carcinoma;   Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Drug: Crizotinib;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Paclitaxel;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis
3 Recruiting LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: LDK378;   Drug: pemetrexed;   Drug: docetaxel
4 Recruiting Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Drug: pemetrexed disodium
5 Recruiting Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Condition: Tumor Pathway Activations Inhibited by Dovitinib
Intervention: Drug: Dovitinib (TKI258)

Indicates status has not been verified in more than two years